|Systematic (IUPAC) name|
|Legal status||Schedule IV(US)|
|(what is this?)|
Camazepam is a benzodiazepine psychoactive drug, marketed under the brand names Albego, Limpidon and Paxor. It is the dimethyl carbamate ester of temazepam, a metabolite of diazepam. While it possesses anxiolytic, anticonvulsant, skeletal muscle relaxant and hypnotic properties it differs from other benzodiazepines in that its anxiolytic properties are particularly prominent but has comparatively limited anticonvulsant, hypnotic and skeletal muscle relaxant properties.
Compared to other benzodiazepines, it has reduced side effects such as impaired cognition, reaction times and coordination. which makes it best suited as an anxiolytic because of these reduced sides effects. With higher doses such as 40 mg of camazepam, impairments similar to those caused by other benzodiazepines manifest as disrupted sleep patterns and impaired cognitive performance. Animal studies have shown camazepam and its active metabolites possess anticonvulsant properties. Skin disorders have been reported with use of camazepam however. Camazepam is believed to increase attention. Unlike other benzodiazepines it does not disrupt normal sleep patterns. Camazepam has been shown in animal experiments to have a very low affinity for benzodiazepine receptors compared to other benzodiazepines. It is almost completely absorbed into the bloodstream after oral administration with, 90 percent bioavailability achieved in humans. Camazepam is metabolised into the active metabolite temazepam. Compared to temazepam, camazepam has shown roughly equal anxiolytic properties, and less anticonvulsant, sedative and motor-impairing properties.